In this chapter, the recent advancements in the mentioned areas of research in pharmacoepigenomics will be highlighted, including the most recently discovered and promising epigenetic therapies that aim to improve NDD treatment. We will focus on a subset of NDDs, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), in which evidence supporting the contribution of pharmacoepigenomics has been best established.
Pharmacoepigenomics in neurodegenerative diseases
Nicoletta Nuzziello;Maria Liguori
2021
Abstract
In this chapter, the recent advancements in the mentioned areas of research in pharmacoepigenomics will be highlighted, including the most recently discovered and promising epigenetic therapies that aim to improve NDD treatment. We will focus on a subset of NDDs, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), in which evidence supporting the contribution of pharmacoepigenomics has been best established.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
